Leptospira noguchiiand Human and Animal Leptospirosis, Southern Brazil

Caracterización molecular de serovariedades de Leptospira aislados de muestras de animales y agua en Colombia

“…The Leptospira noguchii serovars have been isolated from multiple animal species in Argentina, Nicaragua, Barbados, the United States of America and neighboring Panama and Peru, and from humans in the latter three countries (8,19). Interestingly, this serovar was also isolated from two humans (one of whom had severe icteric disease) who both had had contact with dogs and rats and from a dog with a fatal case of leptospirosis in Brazil (20). These results therefore demonstrate the putative importance of canine transmission of this serovar and its capacity to cause severe human disease.…”

First isolation and characterization of Leptospira interrogans serogroup Australis from swine in Brazil

“…First isolation and characterization of Leptospira interrogans serogroup Australis from swine in Brazil to a L. noguchii strain named Hook, which was obtained from a clinical diseased dog in Southern Brazil (Silva et al 2009). Isolation of local strains is required for a definitive epidemiological understanding of their real occurrence.…”

Infection with Leptospira kirschneri Serovar Mozdok: First Report from the Southern Hemisphere

“…The current vaccines, however, are heatkilled whole cells of Leptospira spp., which provide only serovar-specific protection, and only a few countries permit their use. 15 This type of vaccine could be effective in urban areas such as Salvador and São Paulo, where a single serovar is responsible for the majority of human and animal cases 3 ; however, in mixed urban/rural areas such as Pelotas, where leptospirosis is caused by several serovars, [17][18][19][20] novel vaccines capable of inducing a cross-protective response are a necessity. Therefore, characterization of clinical isolates to the serovar level is of crucial importance, not only to understand the epizootiology of the disease but also for the development of novel vaccines and diagnostic tests.…”